Your position
Antimicrobial resistance (AMR) is a global health concern. In recent decades, pan-resistant bacteria have emerged, rendering commonly available antibiotics ineffective. Consequently, many pivotal advancements in modern medicine are now under threat. As the development of new antimicrobials stagnates, there is an urgent need for alternative strategies to identify clinically effective treatments. In this project, we aim to develop a novel strategy for the treatment of antibiotic-resistant pulmonary infections via taking advantage of nanoparticle and mRNA technologies. mRNA technology has gained significant attention in various therapeutic areas, particularly in the development of vaccines for COVID-19. However, the potential of mRNA therapies against antimicrobial resistance has not yet been explored. With this project, we aim to bring the mRNA therapeutics beyond the current state-of-the-art.
Your profile
We expect candidates to have a relevant background in biology, chemistry, nanosciences, or a similar field (Master's degree required). Prior experience in at least one of the followings is a must: microbiology (growth curves, inhibition assays,etc.), molecular biology (mRNA transfection, mammalian cell culture, etc.), nanoformulation development (lipid nanoparticles, polymer nanoparticles, liposomes, etc.). Over the course of the project, the candidate will acquire a wide range of skills in nanoformulation development, mRNA delivery, transfection, microbial and mammalian cell cultures